IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Download PDF Copy

Reviewed

Icon Bioscience, Inc.May 5 2010

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome™ Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.

Title: One Year Results of a Phase 1 Study Evaluating the Safety and Evidence of Efficacy of a Single Intravitreal Injection of the Verisome™ Liquid Drug Delivery System for Sustained Release of Low-Dose Triamcinolone (IBI-20089) in Eyes With Cystoid Macular Edema

Program Number: 6396

Session Date/Time: Thursday, May 6, 2010 from 1:15-3:00pm; Room Grand H

Session Title: Macular Edema – Clinical Trials

Source:

Icon Bioscience, Inc.

Posted in: Device / Technology News | Medical Procedure News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Research shows GLP-1 drugs safeguard vision despite small retinopathy risk

Assessing the impact of the particle drift effect on oral drug absorption using flux tools

A new era of targeted therapy with antibody–drug conjugates

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

The science of silk fibroin and chitosan: Techniques for biomaterials analysis

Squid-inspired technology could replace needles for medications and vaccines

What diet pattern worsens inflammatory bowel disease?

Pregabalin raises heart failure risk in older adults compared to gabapentin, study finds

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.